Q-Line Biotech share price
NSE: QLINEHealthcare Equipment & Supplies
Q-Line Biotech Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2026 · Issue price ₹343
Last close ₹544.45down ₹4.60 (0.84%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹549.05.
28 Oct: open ₹551.00, high ₹567.95, low ₹530.65
Range of traded prices from listing on 29 May 2026 to 28 Oct 2026
₹431.00Low, 29 May 2026₹735.00High, 15 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹1,270 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.79
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 22.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.92
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 42,80067.3% delivered
Results
Consolidated; ₹ crore.Q-Line Biotech half-yearly results
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹198 Crup 37.65%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹34 Crup 61.41%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 17.4%
Revenue by half year
Peak revenue ₹198 Cr, half year to Mar 2026; lowest ₹144 Cr, half year to Sep 2025
Net profit by half year, a loss in red
| ₹ crore | Sep 2025 | Mar 2026 |
|---|---|---|
| Revenue | 144 | 198 |
| Net profit | 21 | 34 |
| Net margin | 14.8% | 17.4% |
Consolidated. The 2 half years from Sep 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026
- Revenue
- ₹342 Cr
- Net profit
- ₹56 Cr
- Net margin
- 16.3%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 342 |
| Net profit | 56 |
| Net margin | 16.3% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Sale of Product ManufacturedSale of Product Manufactured, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹230 Cr67.4%
- Sale of Traded GoodsSale of Traded Goods, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹112 Cr32.6%
Mutual fund holdings
1 fund disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 Abakkus Small Cap FundAbakkus Mutual Fund | 5,13,600 | 1.08% | ₹35.0 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Q-Line Biotech competitors and peers
Medical Equipment & Supplies, 27 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Q-Line Biotech in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Poly MedicurePOLYMED | 14,961 | 47.48 | 4.82 | +18.3% | −11.9% | 10.7% | 9.5% | 0.24% |
 Sahajanand Medical TechnologiesSMT | 4,788 | – | – | – | – | – | – | 0.00% |
 Fischer Medical VenturesFISCHER | 1,863 | 62.21 | – | +196.0% | +354.6% | 8.3% | 10.2% | 0.19% |
 Tarsons ProductsTARSONS | 1,621 | 146.07 | 2.55 | +10.6% | −59.7% | 1.8% | 1.5% | 0.00% |
 Laxmi DentalLAXMIDENTL | 998 | 32.31 | 4.10 | – | – | 13.7% | 12.0% | 0.00% |
 Hemant Surgical IndustriesHSIL | 832 | 45.76 | – | +117.4% | +126.2% | 18.1% | – | 0.00% |
 Vasa DenticityDENTALKART | 721 | – | 4.14 | – | – | – | – | 0.00% |
 Osel DevicesOSELDEVICE | 606 | 20.75 | 2.97 | – | – | 14.3% | – | 0.29% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Q-Line Biotech announcements
Oct 2026
Sep 2026
30 Sep · Meeting
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 550.00 | 574.00 | 545.10 | 549.05 | 561.43 | 75,600 | 75.7% |
| 26 Oct 2026 | 535.00 | 552.10 | 530.15 | 541.60 | 542.03 | 60,000 | 64.7% |
| 23 Oct 2026 | 564.00 | 564.00 | 520.10 | 529.55 | 536.52 | 1,33,600 | 64.7% |
| 22 Oct 2026 | 558.00 | 593.00 | 558.00 | 569.00 | 575.72 | 85,200 | 80.3% |
| 21 Oct 2026 | 605.00 | 612.55 | 551.10 | 572.45 | 568.38 | 1,80,800 | 58.6% |
| 19 Oct 2026 | 630.00 | 630.00 | 597.00 | 600.55 | 608.29 | 58,000 | 68.3% |
| 16 Oct 2026 | 595.00 | 637.90 | 573.05 | 628.85 | 604.50 | 1,80,800 | 49.6% |
| 15 Oct 2026 | 613.00 | 618.95 | 595.00 | 598.30 | 606.50 | 48,400 | 68.6% |
| 14 Oct 2026 | 605.05 | 635.95 | 601.00 | 611.65 | 615.98 | 72,000 | 61.1% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- QLINE
- ISIN
- INE1G2W01011
- Industry
- Healthcare Equipment & Supplies